{"id":"W4390271738","doi":"10.1111/hiv.13593","title":"Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with <scp>HIV</scp>: Real‐world insights from <scp>BICSTaR</scp> cohorts","year":2023,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Merck Canada; Moderna; Novavax; Gilead Sciences; Pfizer; Mylan; ViiV Healthcare; Eli Lilly and Company","keywords":"Emtricitabine; Medicine; Tenofovir alafenamide; Internal medicine; Regimen; Tolerability; Population; Adverse effect; Clinical endpoint; Human immunodeficiency virus (HIV); Viral load; Clinical trial; Immunology; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000741975,0.0007075075,0.001951658,0.00142899,0.0001597527,0.00001707166,0.0002055528,0.0002096613,0.00003876689],"category_scores_gemma":[0.0007358624,0.0004801216,0.0001078344,0.003193783,0.0003836619,0.0001824074,0.000148188,0.0004895488,0.0001103744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003997481,"about_ca_system_score_gemma":0.0004706881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001714898,"about_ca_topic_score_gemma":0.00437847,"domain_scores_codex":[0.995878,0.0002667963,0.0009938158,0.0009804494,0.001081671,0.0007992547],"domain_scores_gemma":[0.994721,0.003459099,0.0003447216,0.0007046515,0.0002386193,0.0005318942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003444838,0.0004176914,0.9711265,0.0004819691,0.0006523047,0.001270321,0.009748664,0.00005182968,0.003056558,0.000449205,0.01150122,0.0008992465],"study_design_scores_gemma":[0.01451408,0.0005671867,0.9620551,0.002630182,0.0006662887,0.00003282633,0.002862658,0.0003884314,0.002531019,0.0004902548,0.01312643,0.0001354799],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785157,0.001293738,0.0001588982,0.001272936,0.0002380763,0.001892766,0.00009160567,0.0002585332,0.01627769],"genre_scores_gemma":[0.9746162,0.001974569,0.0005602636,0.0001649996,0.0002687135,0.0002207081,0.001770122,0.0001257988,0.02029867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0141696,"threshold_uncertainty_score":0.999765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007947414303070334,"score_gpt":0.2350739832618673,"score_spread":0.227126568958797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}